Therefore, we conclude that BET proteins may act as master regulators of both NFκB and STAT signaling, and that both of these pathways may contribute to a high expression of c-MYC and BCL2A1 in DLBCL. The gene discussed is BCL2A1; the disease is diffuse large B-cell lymphoma.